Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002798 · ClinicalTrials.gov registry record · Phase 3

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
880
Enrollment target
1
Study location

NCT00002798 is a Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 880 participants, above the 77-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (1043% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002798, a Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
880 participants
Enrollment target
1
Study location

Study Summary

Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome

Interventions

  • DRUG fludarabine phosphate
  • PROCEDURE allogeneic bone marrow transplantation
  • DRUG asparaginase
  • DRUG daunorubicin hydrochloride
  • DRUG therapeutic hydrocortisone

Study Locations (1)

California

  • Children's Oncology Group - Arcadia

Trial Details

FieldValue
Enrollment Target 880 participants
Start Date 1996-08
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00002798

The ClinicalTrials.gov registry entry for NCT00002798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 77-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (1043% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which fludarabine phosphate is the first listed.

NCT00002798 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00002798 about?

NCT00002798 is a clinical study titled "Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome". Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividin...

What is the current status of trial NCT00002798?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 1996-08.

What conditions does trial NCT00002798 study?

This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Childhood Myelodysplastic Syndromes, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a).

What interventions are being tested in trial NCT00002798?

The interventions under investigation include: fludarabine phosphate (DRUG), allogeneic bone marrow transplantation (PROCEDURE), asparaginase (DRUG), daunorubicin hydrochloride (DRUG), therapeutic hydrocortisone (DRUG).

Who is sponsoring clinical trial NCT00002798?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002798 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Myelomonocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.